|LIVE POLLING – MORNING||Click here to participate in the MORNING live polling.|
|LIVE POLLING – AFTERNOON||Click here to participate in the AFTERNOON live polling.|
|PROGRAMME||Download a copy of today’s programme here.|
|FEEDBACK FORM||We would be really grateful if you could let us know what you thought about today’s event by completing the survey here. Your feedback helps us plan future events. Thank you!|
https://www.yourgenome.org – Helping you discover more about DNA, genes and genomes, and the implications for our health and society.
in2scienceUK is an award winning charity which empowers students from disadvantaged backgrounds to achieve their potential and progress to STEM and research careers through high quality work placements and careers guidance. in2scienceUK supports young people from low income backgrounds to progress to university to study science, technology and engineering and maths degrees and progress to STEM careers.
|Progress Educational Trust
Progress Educational Trust (PET) is a charity founded in 1992 to advance public understanding of science, law and ethics in the fields of human genetics, human reproduction, embryology and stem cell research. Funded by grants and public donations PET aims to help people in the UK and worldwide. OUR VISION IS… to improve the choices for people affected by infertility or genetic conditions. OUR MISSION IS… to educate and to debate the responsible application of reproductive and genetic science. We hold regular, free public events at which we welcome school parties. If you need to research a particular topic for an assignment, you should also check out PET’s flagship publication BioNews – www.bionews.org.uk – a weekly digest of news, comment and reviews read by around 18,000 people.You can subscribe to BioNews by email for FREE at www.bionews.org.uk/subscribe. Find us on Facebook at www.facebook.com/ProgressEducationalTrust. Follow us on Twitter @BioNewsUK.
PARTNERS AND SPONSORS
|The Biochemical Society
The Biochemical Society promotes the future of molecular biosciences; facilitating the sharing of expertise, supporting the advancement of biochemistry and molecular biology, and raising awareness of their importance in addressing societal grand challenges.
Immunocore is the world’s leading T cell receptor (TCR) company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, through its pioneering soluble TCR technology platform. The scientific expertise at Immunocore spans the entire process of drug development. From the discovery and validation of suitable disease targets, through to the design and engineering of immune-activating TCR-based reagents, and preclinical and clinical assessment.
Using our unique LentiVector® delivery platform, we have created a valuable portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. We have strong partnerships with Novartis, Bioverativ (part of the Sanofi group), Immune Design, Boehringer Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium and Orchard Therapeutics, providing them with access to our intellectual property, state-of-the-art production facilities and expertise, and, in addition, we have licensed products and technology rights to Sanofi and Axovant. These partnerships provide us with multiple income streams, consisting of upfront milestone payments, development and production fees and potential royalties on future product sales. We plan to progress our wholly-owned products via spin-outs and out-licensing opportunities, while continuing to invest in our LentiVector® platform. We plan to continue our preclinical R&D to discover new potential products.
PsiOxus aims to be the world’s leading cancer gene therapy company, delivering medicines of value to patients with cancer.
We focus on discovering and developing innovative gene-based immuno-oncology treatments for solid tumors using our proprietary intravenously administered T-SIGn virus platform. Our portfolio of differentiated gene therapy products are all delivered systemically but act locally within the tumor.
At PsiOxus we are advancing our internal early and clinical stage candidates and establishing strategic partnerships with immuno-oncology leaders to bring our cancer gene therapy products to patients.
Theolytics is a pre-clinical stage biotechnology company developing next-generation oncolytic viral therapies.
|The European Society of Gene and Cell Therapy
The European Society of Gene and Cell Therapy (ESGCT) promotes basic and clinical research in gene therapy, cell therapy and genetic vaccines by facilitating education, the exchange of information and technology, and by serving as a professional adviser to stakeholder communities and regulatory bodies in Europe.